Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Ryvu Therapeutics SA (RVU) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.245x
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.245x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-17.42 Million) by net assets (zł71.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ryvu Therapeutics SA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyeryong Const
KO:013580
|
-0.111x |
|
Dinhvu Port Investment Development JSC
VN:DVP
|
0.026x |
|
HKScan Oyj Series A
LSE:0ISM
|
0.009x |
|
First Real Estate Investment Trust of New Jersey Inc
PINK:FREVS
|
0.090x |
|
Itafos Inc
PINK:MBCF
|
0.086x |
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
0.026x |
|
KNIGHTS GROUP HOL LS-002
F:77Q
|
N/A |
|
Kudelski
SW:KUD
|
-0.143x |
Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł143.88 Million | zł-129.48 Million | -0.900x | -176.29% |
| 2023-12-31 | zł259.59 Million | zł-84.55 Million | -0.326x | -624.62% |
| 2022-12-31 | zł343.39 Million | zł21.32 Million | 0.062x | +118.18% |
| 2021-12-31 | zł169.42 Million | zł-57.87 Million | -0.342x | -618.46% |
| 2020-12-31 | zł223.72 Million | zł-10.64 Million | -0.048x | +67.28% |
| 2019-12-31 | zł119.76 Million | zł-17.40 Million | -0.145x | +22.25% |
| 2018-12-31 | zł194.86 Million | zł-36.42 Million | -0.187x | -208.91% |
| 2017-12-31 | zł64.00 Million | zł10.98 Million | 0.172x | +252.23% |
| 2016-12-31 | zł55.71 Million | zł-6.28 Million | -0.113x | +67.84% |
| 2015-12-31 | zł46.88 Million | zł-16.43 Million | -0.350x | +33.84% |
| 2014-12-31 | zł9.25 Million | zł-4.90 Million | -0.530x | +99.76% |
| 2013-12-31 | zł3.13 Million | zł-694.94 Million | -222.129x | -13705.80% |
| 2012-12-31 | zł5.53 Million | zł-8.90 Million | -1.609x | -208.42% |
| 2011-12-31 | zł11.46 Million | zł-5.98 Million | -0.522x | +78.85% |
| 2010-12-31 | zł1.50 Million | zł-3.71 Million | -2.467x | -- |